Sleep Disorders Treatment Drugs Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 – 2034
Report ID: GMI4453
Download Free PDF
Authors:
Monali Tayade,
Sleep Disorders Treatment Drugs Market Size
The global sleep disorders treatment drugs market had a significant revenue in 2024 and is expected to grow at a CAGR from 2025-2034, due to the increasing awareness regarding sleep health, increasing diagnoses of sleep disorders, and increasing availability of medication solutions. According to Sleep Foundation.org, Obstructive sleep apnea (OSA) affects over one billion adults around the globe, with studies showing it is estimated that 80-90% of patients are undiagnosed.
Sleep disorders - such as insomnia, obstructive sleep apnea, narcolepsy, and restless leg syndrome - impact millions of people irrespective of their demographic or lifestyle factors, impacting the quality of life while also creating increased risk for comorbidities including depression, obesity, and cardiovascular disease. The increased elderly populations at greater risk for being impacted by disrupted sleep cycles are also a driving force in this market expansion.
On top of this, increased stress, poor sleep hygiene, and unlimited access to electronic devices have driven the increased level of sleep disorders that younger populations experience daily. Consequently, the demand for targeted pharmaceutical treatments has boomed, including benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists that result in specific treatment. In addition, recent pharmaceutical product development advancements and increased funding for neuropsychiatric products are evolving the market landscape. Although there are concerns with medication dependence, regulatory restrictions, and limited access to the discipline of sleep medicine in low socioeconomic regions, increased awareness of sleep health overall seems to outweigh these challenges.
Sleep Disorders Treatment Drugs Market Trends
The biggest trend likely within this treatment domain is the ever-pressing demand for safer, non-addictive therapies to replace sedative-oriented therapies such as melatonin receptor agonists, and orexin receptor antagonists, which provide useful therapy without the fear of addiction. As well, researchers and pharmaceuticals are assessing compounds looking to target the neurological factors causing sleep disorders, which should further enable precise, longer recovery.
Further, personalized medicine is gaining momentum, mainly in personalized therapy around genetics and behavior. The predicted increase in combination therapy that brings behavioral therapy with pharmacological treatment is a much larger lens of total treatment. Mark my words, this market is accelerating toward better, more patient-centered treatment models.
Furthermore, there is also a noteworthy shift to non-habit-forming medications available in the marketplace, such as the orexin receptor antagonists daridorexant and lemborexant, which have been approved respectively, are shown to be effective comparisons of treatment options for insomnia, but with lower dependency risk.
There is a growing use of Digital health technologies, including mobile applications and wearable devices, that help with diagnosis or for individualized therapy management plans, which demonstrates that there is a current re-evaluation of the process toward precision medicine as it comes to how sleep disorders are treated. These are a few examples of the movement toward the more holistic and patient-centered healthcare management of sleep disorders.
Sleep Disorders Treatment Drugs Market Analysis
The sleep disorders treatment drugs market from intrinsic sleep disorders-related segment had the highest market share in 2024 and is expected to continue to do so through 2034. With origins steeped in physiological or neurological issues manifesting in the body, intrinsic sleep disorders feature insomnia, narcolepsy, idiopathic hypersomnia, and restless legs syndrome, to name a few. Of these disorders, insomnia is by far the most common, affecting approximately > 30% of the adult population globally, at least once in their lives. The increased prevalence of chronic stress, mental health conditions such as anxiety and depression, and increasingly unregulated work-life schedules, has contributed to the number of persons diagnosed with intrinsic disorders is increasing.
In addition to these factors, unknown technological disruptions such as excessive screen time or too many night shifts destroying the circadian rhythm and disrupting the sleep-wake cycle, sleep disorders are becoming more commonplace. There is a myriad of pharmaceutical agents for treating intrinsic sleep disorders, whereby medications resulting in benzodiazepines, orexin antagonists, and melatonin-based pharmacotherapy designed to improve sleep quality, sleep-wake cycles, and daytime sleepiness.
The sleep disorders treatment drugs market from melatonin receptor agonists segment held a significant revenue share in 2024 and is projected to see steady growth through 2034. Melatonin receptor agonists are effective because they mimic the endogenous physiologic action of melatonin, a naturally occurring hormone regulating the sleep-wake cycle, particularly effective in sleep onset insomnia and circadian rhythm disorders. Unlike conventional sedatives, melatonin receptor agonists (such as ramelteon and tasimelteon) are non-scheduled, non-habit forming drugs that consist of minimal risk of dependent use, which improves their likability amongst health care providers as well as patients.
The absence of negative side effects and the assurance to maintain sleep architecture with minimal next-day impairment are additional characteristics of melatonin receptor agonists that have led to being widely used–especially in older populations sensitive to sedative-hypnotic drugs.
Additionally, a growing focus on safer, more naturalistic evidence-based therapies to treat chronic conditions has increased acceptance of melatonin receptor agonists in managed care, particularly when the therapy includes long-term management plans. The increase in jet lag, shift work disorder, and delayed sleep phase disorder—syndromes that closely relate to current modern work lifestyles—has also driven the demand for circadian rhythm-based therapies. Related to this topic, clinical studies are receiving funding for exploring the evidence-based therapeutic capability of melatonin receptor agonists in populations that include pediatric insomnia and neurodevelopment sleep disorders, providing other therapeutic avenues for considering a growing market segment.
Asia Pacific sleep disorders treatment drugs market is expected to achieve the fastest CAGR from 2025 to 2034. The region's mass-market potential and growing population (rapidly aging), rapid urbanization, increasing work-related stress, and the relatively recent adoption of Westernized lifestyles (particularly with technology use and exposure to artificial light), have contributed to the increases in sleep-related health issues. In Asia Pacific countries, such as China, Japan, India, and South Korea, traditional lifestyles involve sleeping well with natural light.
However, lifestyle transformations have shifted populations towards irregular sleep patterns and increased insomnia, sleep apnea, and circadian issues. Increased mental health awareness, sleeping hygiene, and access to healthcare services have contributed to increased attention to sleep disorders. In the last few years, the combination of awareness and access has driven overall demand for sleep disorder treatments, including pharmaceutical and alternative methods.
Furthermore, as healthcare in Asia has improved and access to quality healthcare services continues to improve, the whole subject of inheritance and genomic variations of this population is becoming more of a focus for novel treatments. Other potential pharmaceutical-based treatments in involved with discovery and development based on genetic and environmental factors, both of which are important to the Asia Pacific population.
Sleep Disorders Treatment Drugs Market Share
The sleep disorders treatment drugs industry players include:
Key players in the sleep disorders treatment drugs market use various strategies to enhance their market position. This includes sustained investment in R&D to develop new, innovative therapies that are non-addictive and have favorable safety profiles and an improved side effect profile. Advancing the growth pipeline via strategic partnerships, licensing agreements, and mergers is also being used companies are focusing on growing their drug pipeline for the rapid reduction of business, through the development of emerging countries, including India and China. Product differentiation is also occurring in Sleep Disorders Treatments such as through novel drug delivery systems (sublingual tablets and extended-release formulation) that can help to enhance adherence by the patients.
Sleep Disorders Treatment Drugs Industry News
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →